Companies Join Forces to Showcase how AI Algorithms can Progressively be Adopted in Study Conduct, at DPharm 2018
Pioneering partners Cmed and Innovative Physics have combined forces to showcase The Real Time Medical Imaging Users Tool Kit®, which uses artificial intelligence to support secure, rapid diagnostics in clinical trials, at DPharm 2018.
Cmed, an innovative, technology-led clinical research organisation, has been working with global hi-tech company Innovative Physics which has a long history in the use and application of artificial intelligence in a variety of industries.
The companies have worked together to combine the use of pattern recognition, implemented through a statistical computational engine with Cmed’s unique clinical data suite encapsia® to support the rapid and accurate interpretation of lung CT scans. Using the combined software and clinical data suite, the partners have been able to assess the CT scans of over 1,500 patients and locate and measure three dimensional nodules quickly - with the aim of supporting an improved speed and accuracy of interpretation. This approach could benefit the current lung cancer diagnostic process.
The findings mean that results can be identified rapidly and tracked over time to enable Investigators to make faster and more accurate interpretations, with the data immediately available to sponsors and medical monitors.
At DPharm, visitors to their stand will be able to see the demo for themselves and find out more about how this innovative approach can be applied to transform and modernise clinical diagnostics and how it can be used in clinical trials.
Chief Technology Officer for Cmed, Timothy Corbett-Clark, said: “Our next generation clinical data suite encapsia®has already inspired and driven real progress in clinical trials. Now, with the application of artificial intelligence through Innovative Physics’ unique software, operated with encapsia® we look set to transform clinical trials.”
Mike Anderson, Chief Executive Officer of Innovative Physics said: “While our clinical studies with Cmed have focused on lung cancer diagnostics, the application of artificial intelligence has endless possibilities in both trials and in clinical diagnosis and the potential to advance the precision and speed of the process. We are already in talks for a similar approach around prostate cancer and would be keen to meet and share more about our unique approach with visitors to DPharm.”
Cmed and Innovative Physics can be found at booth #44 at DPharm 2018, in Boston, Massachusetts, USA between September 25-26th2018.
ENDS.
Press Contact at DPharm Conference, Booth #44
Timothy Corbett-Clark
Chief Technology Officer
Email tcorbettclark@cmedtechnology.com
Press Contact for Cmed
Claudia Cernea
Marketing Specialist
Email ccernea@cmedgroup.com
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
